

Reference:	FOI.12475.23
Subject:	Dermatological conditions
Date of Request:	18 August 2023

Requested:

1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:
 - Abrocitinib
 - Acitretin
 - Alitretinoin
 - Azathioprine
 - Baricitinib
 - Ciclosporin
 - Dupilumab
 - Methotrexate
 - Mycophenolate mofetil
 - Pimecrolimus
 - Phototherapy (UVB or PUVA)
 - Tacrolimus ointment
 - Tralokinumab
 - Upadacitinib
2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?
3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:
 - a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?
 - b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib?
 - c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
 - d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretinoin, Pimecrolimus or Tacrolimus?

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of dermatology patients treated with the listed medications, during the period 1 April to 31 July 2023.

Medication	Number
Abrocitinib	0
Acitretin	48

Alitretinoin	*
Azathioprine	13
Baricitinib	0
Ciclosporin	9
Dupilumab	56
Methotrexate	60
Mycophenolate mofetil	*
Pimecrolimus	*
Phototherapy (UVB or PUVA)	0
Tacrolimus ointment	*
Tralokinumab	*
Upadacitinib	*

2. The UHB confirms that fifty one (51) dermatology patients were treated with the medication, Dupixent, during the period 1 December 2022 to 31 March 2023.

3a. The UHB confirms that of the dermatology patients treated with Dupilumab during the period 1 December 2022 to 31 March 2023, forty five (45) received Dupilumab during the period 1 April to 31 July 2023.

3b. to 3d. The UHB is unable to provide you with the exact number of dermatology patients, due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.